Vilaprisan - Bayer HealthCare Pharmaceuticals
Alternative Names: BAY 1002670; Bayer-sPRM; S-PRAnt; S-PRM; sPRMLatest Information Update: 05 Nov 2023
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class Antineoplastics; Antiprogestogens; Infertility therapies; Small molecules; Sulfones
- Mechanism of Action Progesterone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Endometriosis; Uterine leiomyoma
Most Recent Events
- 30 Jun 2022 Bayer terminates the phase III ASTEROID 4 trial in Uterine-leiomyoma in the US, Czech Republic, Japan, Russia and Ukraine due to a change in the development program (NCT03400956)
- 06 Jun 2022 Bayer terminates the phase III ASTEROID 8 trial in Uterine leiomyoma in Japan due to changes in development plan of vilaprisan (PO) (NCT03476928)
- 10 Nov 2021 Phase-III clinical trials in Uterine leiomyoma in United Kingdom, Taiwan, Spain, Sweden, Slovakia, Portugal, Poland, Norway, Netherlands, Lithuania, South Korea, Italy, Ireland, Germany, Denmark, Czech Republic, Canada, Bulgaria, Belgium and Australia (PO) (NCT03240523).